KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.
Acute-kidney-injury drug with phase 1 done and phase 2a under way, at Series A: a clinical-stage asset approaching EFung's phase 2 sweet spot.
Evidence from the records
- “drug developers with phase 2/3 assets”
- “Drug for acute kidney injury”
- “phase 2a under way in Korea”
- Intro path
- Pleryon Therapeutics (EFung portfolio)
- First step
- Send phase 1 data and the phase 2a design to EFung's CSO.